Search

Meeting Coverage:

American Academy of Ophthalmology

AAO: 2024

Fellow-Eye Dosing of ABBV-RGX-314 Gene Therapy

Arshad M. Khanani, MD, MA, FASRS

Show Description +

Dr. Khanani explains the results of a fellow-eye bilateral dosing study of investigational ABBV-RGX-314 (Regenxbio/Abbvie) gene therapy for wet AMD. Subretinal delivery of the drug led to a 97% reduction in anti-VEGF treatment burden at 9 months.

Posted: 10/22/2024

Keywords:

retina-meeting-recap

•

Abbvie

•

REGENXBIO

•

ABBV-RGX-314

•

Gene Therapy

•

Wet AMD

•

Age-Related Macular Degeneration (AMD)

•

treatment burden

•

Subretinal

•

Anti-VEGF

Up Next

Managing Elderly Patients With Advanced, Progressive Disease

Managing Elderly Patients With Advanced, Progressive Disease

Jody Piltz-Seymour, MD

Home Testing Ready for Prime Time?

Home Testing Ready for Prime Time?

Rachel G. Simpson, MD

Association Between GLP-1 Receptor Agonists Exposure and IOP Change

Association Between GLP-1 Receptor Agonists Exposure and IOP Change

Qi N. Cui, MD, PhD

Expanding Adjustable IOL Technology

Expanding Adjustable IOL Technology

Mitchell Weikert, MD

Presbyopia-Correcting IOLs: New Categories?

Presbyopia-Correcting IOLs: New Categories?

Daniel H. Chang, MD

$Lenticule Extraction and Corneal Refractive Surgery$

Lenticule Extraction and Corneal Refractive Surgery

Audrey Talley Rostov, MD

Genetic Testing for Primary Open-Angle Glaucoma

Genetic Testing for Primary Open-Angle Glaucoma

Anthony P. Khawaja, MBBS

Glaucoma Lasers: What’s New?

Glaucoma Lasers: What’s New?

Sarah Van Tassel, MD

Visual Field Progression in the LiGHT Trial

Visual Field Progression in the LiGHT Trial

Gus Gazzard, MA(Cantab), MD, MBBChir, FRCOphth

$Intense Pulsed Light Therapy and Refractive Surgery$

Intense Pulsed Light Therapy and Refractive Surgery

Jorge Alio Del Barrio, MD, PhD

$Frequency and Risk Factors for Ocular Pain After Refractive Surgery$

Frequency and Risk Factors for Ocular Pain After Refractive Surgery

Jason Betz, BS

Digital Imaging and Software Revolution in Ophthalmology

Digital Imaging and Software Revolution in Ophthalmology

Cathleen McCabe, MD

Sequential CAIRS and Combined Wavefront-Guided PRK and CXL

Sequential CAIRS and Combined Wavefront-Guided PRK and CXL

Shady T. Awwad, MD

Causes and Prevention of TASS During Anterior Segment Surgery

Causes and Prevention of TASS During Anterior Segment Surgery

Nick Mamalis, MD

Technology-Driven Tools for Improving Patient Care and Physician Wellness

Technology-Driven Tools for Improving Patient Care and Physician Wellness

Renee Bovelle, MD

36 Months of GA Therapy with Pegcetacoplan

36 Months of GA Therapy with Pegcetacoplan

Dilsher S. Dhoot, MD

A Look at Topline Data: EYP-1901

A Look at Topline Data: EYP-1901

Carl D. Regillo, MD

Updates on a Novel Oral Therapy for DME

Updates on a Novel Oral Therapy for DME

Joel A. Pearlman, MD, PhD

Extension Data for High-Dose Aflibercept

Extension Data for High-Dose Aflibercept

Diana Do, MD

The Promise of a Wnt Agonist

The Promise of a Wnt Agonist

Charles C. Wykoff, MD, PhD

Visual Function with Mac-Tel Type 2 Treatment

Visual Function with Mac-Tel Type 2 Treatment

Roger A. Goldberg, MD, MBA

The Risk of PVR Revealed

The Risk of PVR Revealed

Mathew W. MacCumber, MD, PHD

A Novel Scleral Buckling Technique

A Novel Scleral Buckling Technique

Maria H. Berrocal, MD

The Challenges of Epiretinal Membrane Surgery

The Challenges of Epiretinal Membrane Surgery

Yasha S. Modi, MD

The 2024 Charles L Schepens MD Lecture

The 2024 Charles L Schepens MD Lecture

Steve Charles, MD, FACS, FICS

Back to All Videos

Fellow-Eye Dosing of ABBV-RGX-314 Gene Therapy

Arshad M. Khanani, MD, MA, FASRS

Dr. Khanani explains the results of a fellow-eye bilateral dosing study of investigational ABBV-RGX-314 (Regenxbio/Abbvie) gene therapy for wet AMD. Subretinal delivery of the drug led to a 97% reduction in anti-VEGF treatment burden at 9 months.

Posted: 10/22/2024

Keywords:

retina-meeting-recap

•

Abbvie

•

REGENXBIO

•

ABBV-RGX-314

•

Gene Therapy

•

Wet AMD

•

Age-Related Macular Degeneration (AMD)

•

treatment burden

•

Subretinal

•

Anti-VEGF

Please log in to leave a comment.

More From AAO: 2024 Coverage

36 Months of GA Therapy with Pegcetacoplan

36 Months of GA Therapy with Pegcetacoplan

Dilsher S. Dhoot, MD

A Look at Topline Data: EYP-1901

A Look at Topline Data: EYP-1901

Carl D. Regillo, MD

Updates on a Novel Oral Therapy for DME

Updates on a Novel Oral Therapy for DME

Joel A. Pearlman, MD, PhD

Extension Data for High-Dose Aflibercept

Extension Data for High-Dose Aflibercept

Diana Do, MD

Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of AAO: 2024.